Acrivon Therapeutics, Inc. (ACRV)

NASDAQ: ACRV · IEX Real-Time Price · USD
12.50
-0.35 (-2.72%)
At close: Dec 1, 2022 3:58 PM
12.70
+0.20 (1.60%)
After-hours: Dec 1, 2022 6:25 PM EST
-2.72%
Market Cap 273.19M
Revenue (ttm) n/a
Net Income (ttm) -19.82M
Shares Out 18.81M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,883
Open 12.52
Previous Close 12.85
Day's Range 12.4 - 12.76
52-Week Range 10.9 - 20.7
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACRV

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candid... [Read more]

Industry Biotechnology
IPO Date Nov 15, 2022
CEO Peter Blume-Jensen, M.D., Ph.D.
Employees 35
Stock Exchange NASDAQ
Ticker Symbol ACRV
Full Company Profile

Financial Performance

Financial Statements

News

Acrivon Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncol...

2 weeks ago - GlobeNewsWire

Acrivon Therapeutics sets IPO price range

Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the symbol ACRV. With 5.9 million shares in the...

4 weeks ago - Market Watch